CSF OX-A levels were found to directly correlate with tau levels in healthy control subjects (Osorio et al., 2016; Gabelle et al., 2017; Shimizu et al., 2020) and in AD patients (Deuschle et al., 2014). Here, MAPT is linked to Alzheimer disease.